IL13RA2 and cancer: As PNI is associated with the generation of pain experienced by the PDAC patients and associated with IL-13Rα2 overexpression, we hypothesize that IL-13Rα2-targeted therapy may be a useful and potent approach to inhibiting cancer invasion, metastasis and PNI, hence, it may prolong the survival of PDAC patients and alleviate their pain.